Tariq Ahmad1, Keyanna Jackson1, Veena S Rao1, W H Wilson Tang2, Meredith A Brisco-Bacik3, Horng H Chen4, G Michael Felker5, Adrian F Hernandez5, Christopher M O'Connor6, Venkata S Sabbisetti7, Joseph V Bonventre7, F Perry Wilson8, Steven G Coca9, Jeffrey M Testani10. 1. Sections of Cardiovascular Medicine (T.A., K.J., V.S.R., J.M.T.). 2. Section of Heart Failure and Cardiac Transplantation, The Cleveland Clinic, OH (W.H.W.T.). 3. Cardiology Division, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (M.A.B.-B.). 4. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C.). 5. Duke University Medical Center and Duke Heart Center, Durham, NC (G.M.F., A.F.H.). 6. Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.). 7. Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA (V.S.S., J.V.B.). 8. Nephrology (F.P.W.), Yale University School of Medicine, New Haven, CT. 9. Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY (S.G.C.). 10. Sections of Cardiovascular Medicine (T.A., K.J., V.S.R., J.M.T.) jeffrey.testani@yale.edu.
Abstract
BACKGROUND:Worsening renal function (WRF) in the setting of aggressive diuresis for acute heart failure treatment may reflect renal tubular injury or simply indicate a hemodynamic or functional change in glomerular filtration. Well-validated tubular injury biomarkers, N-acetyl-β-d-glucosaminidase, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1, are now available that can quantify the degree of renal tubular injury. The ROSE-AHF trial (Renal Optimization Strategies Evaluation-Acute Heart Failure) provides an experimental platform for the study of mechanisms of WRF during aggressive diuresis for acute heart failure because the ROSE-AHF protocol dictated high-dose loop diuretic therapy in all patients. We sought to determine whether tubular injury biomarkers are associated with WRF in the setting of aggressive diuresis and its association with prognosis. METHODS:Patients in the multicenter ROSE-AHF trial with baseline and 72-hour urinetubular injury biomarkers were analyzed (n=283). WRF was defined as a ≥20% decrease in glomerular filtration rate estimated with cystatin C. RESULTS: Consistent with protocol-driven aggressive dosing of loop diuretics, participants received a median 560 mg IV furosemide equivalents (interquartile range, 300-815 mg), which induced a urine output of 8425 mL (interquartile range, 6341-10 528 mL) over the 72-hour intervention period. Levels of N-acetyl-β-d-glucosaminidase and kidney injury molecule 1 did not change with aggressive diuresis (both P>0.59), whereas levels of neutrophil gelatinase-associated lipocalin decreased slightly (-8.7 ng/mg; interquartile range, -169 to 35 ng/mg; P<0.001). WRF occurred in 21.2% of the population and was not associated with an increase in any marker of renal tubular injury: neutrophil gelatinase-associated lipocalin (P=0.21), N-acetyl-β-d-glucosaminidase (P=0.46), or kidney injury molecule 1 (P=0.22). Increases in neutrophil gelatinase-associated lipocalin, N-acetyl-β-d-glucosaminidase, and kidney injury molecule 1 were paradoxically associated with improved survival (adjusted hazard ratio, 0.80 per 10 percentile increase; 95% confidence interval, 0.69-0.91; P=0.001). CONCLUSIONS: Kidney tubular injury does not appear to have an association with WRF in the context of aggressive diuresis of patients with acute heart failure. These findings reinforce the notion that the small to moderate deteriorations in renal function commonly encountered with aggressive diuresis are dissimilar from traditional causes of acute kidney injury.
RCT Entities:
BACKGROUND: Worsening renal function (WRF) in the setting of aggressive diuresis for acute heart failure treatment may reflect renal tubular injury or simply indicate a hemodynamic or functional change in glomerular filtration. Well-validated tubular injury biomarkers, N-acetyl-β-d-glucosaminidase, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1, are now available that can quantify the degree of renal tubular injury. The ROSE-AHF trial (Renal Optimization Strategies Evaluation-Acute Heart Failure) provides an experimental platform for the study of mechanisms of WRF during aggressive diuresis for acute heart failure because the ROSE-AHF protocol dictated high-dose loop diuretic therapy in all patients. We sought to determine whether tubular injury biomarkers are associated with WRF in the setting of aggressive diuresis and its association with prognosis. METHODS:Patients in the multicenter ROSE-AHF trial with baseline and 72-hour urine tubular injury biomarkers were analyzed (n=283). WRF was defined as a ≥20% decrease in glomerular filtration rate estimated with cystatin C. RESULTS: Consistent with protocol-driven aggressive dosing of loop diuretics, participants received a median 560 mg IV furosemide equivalents (interquartile range, 300-815 mg), which induced a urine output of 8425 mL (interquartile range, 6341-10 528 mL) over the 72-hour intervention period. Levels of N-acetyl-β-d-glucosaminidase and kidney injury molecule 1 did not change with aggressive diuresis (both P>0.59), whereas levels of neutrophil gelatinase-associated lipocalin decreased slightly (-8.7 ng/mg; interquartile range, -169 to 35 ng/mg; P<0.001). WRF occurred in 21.2% of the population and was not associated with an increase in any marker of renal tubular injury: neutrophil gelatinase-associated lipocalin (P=0.21), N-acetyl-β-d-glucosaminidase (P=0.46), or kidney injury molecule 1 (P=0.22). Increases in neutrophil gelatinase-associated lipocalin, N-acetyl-β-d-glucosaminidase, and kidney injury molecule 1 were paradoxically associated with improved survival (adjusted hazard ratio, 0.80 per 10 percentile increase; 95% confidence interval, 0.69-0.91; P=0.001). CONCLUSIONS:Kidney tubular injury does not appear to have an association with WRF in the context of aggressive diuresis of patients with acute heart failure. These findings reinforce the notion that the small to moderate deteriorations in renal function commonly encountered with aggressive diuresis are dissimilar from traditional causes of acute kidney injury.
Authors: Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2004-01-07 Impact factor: 24.094
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Jeffrey M Testani; Meredith A Brisco; Jennifer Chen; Brian D McCauley; Chirag R Parikh; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: Sameer Ather; Chirag Bavishi; Mark D McCauley; Amandeep Dhaliwal; Anita Deswal; Sarah Johnson; Wenyaw Chan; David Aguilar; Allison M Pritchett; Kumudha Ramasubbu; Xander H T Wehrens; Biykem Bozkurt Journal: Int J Cardiol Date: 2012-05-25 Impact factor: 4.164
Authors: Meyeon Park; Chi-Yuan Hsu; Alan S Go; Harold I Feldman; Dawei Xie; Xiaoming Zhang; Theodore Mifflin; Sushrut S Waikar; Venkata S Sabbisetti; Joseph V Bonventre; Josef Coresh; Robert G Nelson; Paul L Kimmel; John W Kusek; Mahboob Rahman; Jeffrey R Schelling; Ramachandran S Vasan; Kathleen D Liu Journal: Clin J Am Soc Nephrol Date: 2017-03-02 Impact factor: 8.237
Authors: Katherine Xu; Paul Rosenstiel; Neal Paragas; Christian Hinze; Xiaobo Gao; Tian Huai Shen; Max Werth; Catherine Forster; Rong Deng; Efrat Bruck; Roger W Boles; Alexandra Tornato; Tejashree Gopal; Madison Jones; Justin Konig; Jacob Stauber; Vivette D'Agati; Hediye Erdjument-Bromage; Subodh Saggi; Gebhard Wagener; Kai M Schmidt-Ott; Nicholas Tatonetti; Paul Tempst; Juan A Oliver; Paolo Guarnieri; Jonathan Barasch Journal: J Am Soc Nephrol Date: 2016-12-27 Impact factor: 10.121
Authors: Vishal S Vaidya; Josef S Ozer; Frank Dieterle; Fitz B Collings; Victoria Ramirez; Sean Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J Holder; Norma A Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gérard Maurer; Peter L Goering; Frank D Sistare; Joseph V Bonventre Journal: Nat Biotechnol Date: 2010-05 Impact factor: 54.908
Authors: Stephen J McWilliam; Daniel J Antoine; Venkata Sabbisetti; Robin E Pearce; Andrea L Jorgensen; Yvonne Lin; J Steven Leeder; Joseph V Bonventre; Rosalind L Smyth; Munir Pirmohamed Journal: Biomark Med Date: 2014 Impact factor: 2.851
Authors: Yogesh N V Reddy; Masaru Obokata; Jeffrey M Testani; G Michael Felker; W H Wilson Tang; Omar F Abou-Ezzeddine; Jie-Lena Sun; Hrishikesh Chakrabothy; Steven McNulty; Sanjiv J Shah; Gregory D Lewis; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug Journal: J Card Fail Date: 2019-10-13 Impact factor: 5.712
Authors: Zachary L Cox; Krishna Sury; Veena S Rao; Juan B Ivey-Miranda; Matthew Griffin; Devin Mahoney; Nicole Gomez; James H Fleming; Lesley A Inker; Steven G Coca; Jeff Turner; F Perry Wilson; Jeffrey M Testani Journal: J Card Fail Date: 2020-01-30 Impact factor: 5.712
Authors: Yogesh N V Reddy; Masaru Obokata; Aaron D Jones; Gregory D Lewis; Sanjiv J Shah; Omar F Abouezzedine; Marat Fudim; Brooke Alhanti; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug Journal: J Card Fail Date: 2020-08-19 Impact factor: 5.712